Industry News
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc.…
Read More
Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare…
Read More
Christopher Kata and the TrialStat team are exhibiting at this years Clinical Outsourcing Group Bay Area meeting on October 8th – 9th in booth #13. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #13 at your convenience! We’re looking forward to…
Read More
Late Breaking Surgical Safety Data to be Presented This Week at MDS International Congress of Parkinson’s Disease and Movement Disorders Excerpt from the Press Release: SAN DIEGO and PHILADELPHIA , Sept. 26, 2024 /PRNewswire/ — Aspen Neuroscience announced today that it has successfully completed dosing of the first cohort of patients in the ASPIRO study. Surgical safety data…
Read More
Trial Initiation Marks Septerna’s Transition to a Clinical-Stage Company Developing a Portfolio of Oral Small Molecule GPCR-Targeted Medicines Phase 1 Clinical Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-786 in Healthy Volunteers Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Septerna, a clinical-stage biotechnology company pioneering a new era of…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced positive 28-week data from the open-label extension (OLE)…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor…
Read More
-Results highlight ADI-001’s potential as a best-in-class allogeneic cell therapy for autoimmune disease- -Webcast featuring Dr. Blake Aftab with accompanying presentation available on Company website- Excerpt from the Press Release: REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., Sept. 13, 2024 /PRNewswire/ — Marengo Therapeutics, Inc., a clinical-stage biotech company pioneering a new way to activate T cells targeting the Vβ chain of the T cell receptor to select the optimal T cell subsets against cancer, today announced that it has entered into a clinical study collaboration…
Read More
Excerpt from the Press Release: SAN DIEGO, Sept. 12, 2024 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its ERUDITE™ Phase 2 clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential treatment to improve cognitive impairment in patients with schizophrenia. The ERUDITE study was the second…
Read More